Wockhardt has been penalised ₹16 crore by the Commissioner of Customs for alleged misclassification of exported Active Pharmaceutical Ingredients (APIs). The company intends to appeal the order.

The adjudication order, received on August 21, 2026, imposes significant financial penalties on both the entity and an individual officer. Wockhardt disclosed the development in a filing with stock exchanges on August 25, 2026.

Penalty Breakdown

The Commissioner of Customs, Nhava Sheva-II, imposed the following fines under the Customs Act, 1962:

The ₹10 crore redemption fine was levied in lieu of confiscating the misdeclared goods. Dr. Aravind Y Merwade, an officer of the company, was separately penalised ₹1 crore for his role in the alleged contravention.

What the Numbers Show

The total financial exposure of ₹16 crore is heavily skewed toward the redemption fine, which constitutes approximately 62% of the total liability. This structure indicates that the primary regulatory concern was the valuation or classification of the physical inventory rather than just procedural non-compliance, as the penalty component (₹5 crore) is lower than the value of the goods saved from confiscation.

Company Response

Wockhardt stated that the order has no material impact on its financials, operations, or other activities beyond the monetary penalties. The company expressed confidence in the merits of its case and confirmed it is taking necessary steps to challenge the order before the appropriate appellate authority.

The disclosure noted a delay in submission due to an inadvertent administrative oversight.

Wockhardt reported a consolidated net profit attributable to equity shareholders of ₹106 crore for the quarter ended June 30, 2026 (Q1FY27), marking a significant turnaround from a net loss of ₹90 crore in the corresponding period last year. The pharmaceutical company’s revenue from operations grew by 25.9% year-on-year to ₹929 crore, driven by improved operating efficiency and higher top-line momentum. The Board of Directors approved the unaudited financial results on August 10, 2026, following a limited review by statutory auditors M S K C & Associates LLP.

Financial Performance Overview

Wockhardt’s total income for the quarter stood at ₹960 crore, comprising ₹929 crore from operations and ₹31 crore from other income. This compares to a total income of ₹758 crore in Q1FY26, where operational revenue was ₹738 crore. The company managed its expenses effectively, with total expenses amounting to ₹844 crore, down slightly from ₹843 crore in the previous quarter but significantly lower relative to revenue compared to the prior year.

The key driver of profitability was the expansion in operating margins. While the company incurred a loss before exceptional items and tax of ₹12 crore in Q1FY26, it achieved a profit before tax of ₹116 crore in Q1FY27. Tax expenses for the quarter included a current tax charge of ₹7 crore and a deferred tax charge of ₹2 crore, resulting in the final net profit figure.

Standalone Results

On a standalone basis, Wockhardt reported a net profit after tax of ₹107 crore for Q1FY27, an increase from ₹69 crore in Q1FY26. Standalone revenue from operations rose to ₹561 crore from ₹413 crore in the same period last year, reflecting strong domestic performance. Other income decreased to ₹33 crore from ₹55 crore in the previous quarter, though it remained higher than the ₹25 crore recorded in Q1FY26.

Standalone total income was ₹594 crore, against total expenses of ₹487 crore. The company reported no tax expense for the quarter on a standalone basis. Earnings per share (basic) on a standalone basis were ₹6.62, compared to ₹4.25 in Q1FY26.

Key Operational Highlights

• Revenue Growth: Consolidated revenue increased by nearly 26% year-on-year, indicating robust demand across its pharmaceutical segments.
• Profitability Turnaround: The shift from a consolidated net loss of ₹90 crore to a profit of ₹106 crore highlights improved cost management and operational leverage.
• Auditor Review: The results were subjected to a limited review by M S K C & Associates LLP, Statutory Auditors of the Company, pursuant to Regulation 33 of the SEBI Listing Regulations.

What the Numbers Show

The significant improvement in profitability is primarily attributed to top-line growth outpacing expense inflation. While total expenses rose by 9.6% year-on-year, revenue surged by 25.9%, leading to a substantial widening of the pre-tax margin. The absence of major exceptional items in the current quarter, compared to a charge of ₹97 crore in Q1FY26, also contributed positively to the bottom line. The consistent performance across both standalone and consolidated figures suggests that the turnaround is broad-based rather than isolated to specific subsidiaries.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE049B01025/5e5bb7ab-79cc-4267-9052-276ab8fe58ba.pdf